Mikhail Reibarkh

Mikhail Reibarkh

Auto-generated profile, based on publicly available information

Mikhail Reibarkh

Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Cell
Verified
Journal Article
Closed access
NMNathan J. Moerke
Nathan J. Moerke
HAHuseyin Aktas
Huseyin Aktas
HCHan Chen
Han Chen
SCSonia Cantel
Sonia Cantel
MRMikhail Y. Reibarkh
Mikhail Y. Reibarkh
GWGerhard Wagner
Gerhard Wagner

28 April 2017 in Science
Verified
Journal Article
Closed access
PDF file
DDDaniel A. DiRocco
Daniel A. DiRocco
YJYining Ji
Yining Ji
ESEdward Sherer
Edward Sherer
AKArtis Klapars
Artis Klapars
MRMikhail Reibarkh
Mikhail Reibarkh
IDIan W. Davies
Ian W. Davies
Getting phosphorus into healthy shape: ProTide therapeutics play a trick on the body, getting nucleoside analogs where they need to be by decorating them with unnatural phosphoramidates in place of ordinary phosphates. These compounds pose an unusual synthetic challenge because their configuration must be controlled at phosphorus; most methods have been refined to manipulate the geometry of carbon. DiRocco et al. report a metal-free, small-molecule catalyst that attains high selectivity for nucleoside phosphoramidation by activating both reaction partners. Kinetic studies with an early prototype revealed a double role for the catalyst that inspired the rational design of a more active and selective dimeric structure. Science , this issue p. 426

26 October 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
DSDanielle M. Schultz
Danielle M. Schultz
FLFrançois Lévesque
François Lévesque
DDDaniel A. DiRocco
Daniel A. DiRocco
MRMikhail Reibarkh
Mikhail Reibarkh
YJYining Ji
Yining Ji
IDIan W. Davies
Ian W. Davies

13 February 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLisa Lindqvist
Lisa Lindqvist
MOMonika Oberer
Monika Oberer
MRMikhail Reibarkh
Mikhail Reibarkh
RCRegina Cencic
Regina Cencic
MBMarie-Eve Bordeleau
Marie-Eve Bordeleau
JPJerry Pelletier
Jerry Pelletier
RNA helicases represent a large family of proteins implicated in many biological processes including ribosome biogenesis, splicing, translation and mRNA degradation. However, these proteins have little substrate specificity, making inhibition of selected helicases a challenging problem. The prototypical DEAD box RNA helicase, eIF4A, works in conjunction with other translation factors to prepare mRNA templates for ribosome recruitment during translation initiation. Herein, we provide insight into the selectivity of a small molecule inhibitor of eIF4A, hippuristanol. This coral-derived natural product binds to amino acids adjacent to, and overlapping with, two conserved motifs present in the carboxy-terminal domain of eIF4A. Mutagenesis of amino acids within this region allowed us to alter the hippuristanol-sensitivity of eIF4A and undertake structure/function studies. Our results provide an understanding into how selective targeting of RNA helicases for pharmacological intervention can be achieved.

16 November 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BMBenchun Miao
Benchun Miao
ISIgor Skidan
Igor Skidan
JYJinsheng Yang
Jinsheng Yang
ALAlexey Lugovskoy
Alexey Lugovskoy
MRMikhail Reibarkh
Mikhail Reibarkh
ADAlexei Degterev
Alexei Degterev
The PI3-kinase (PI3K) pathway regulates many cellular processes, especially cell metabolism, cell survival, and apoptosis. Phosphatidylinositol-3,4,5-trisphosphate (PIP3), the product of PI3K activity and a key signaling molecule, acts by recruiting pleckstrin-homology (PH) domain-containing proteins to cell membranes. Here, we describe a new structural class of nonphosphoinositide small molecule antagonists (PITenins, PITs) of PIP3–PH domain interactions (IC 50 ranges from 13.4 to 31 μM in PIP3/Akt PH domain binding assay). PITs inhibit interactions of a number of PIP3-binding PH domains, including those of Akt and PDK1, without affecting several PIP2-selective PH domains. As a result, PITs suppress the PI3K-PDK1-Akt pathway and trigger metabolic stress and apoptosis. A PIT-1 analog displayed significant antitumor activity in vivo, including inhibition of tumor growth and induction of apoptosis. Overall, our studies demonstrate the feasibility of developing specific small molecule antagonists of PIP3 signaling.

1 June 2012 in Cell Reports
Verified
Journal Article
Open access
RLRafael E. Luna
Rafael E. Luna
HAHaribabu Arthanari
Haribabu Arthanari
HHHiroyuki Hiraishi
Hiroyuki Hiraishi
JNJagpreet Nanda
Jagpreet Nanda
PMPilar Martin-Marcos
Pilar Martin-Marcos
GWGerhard Wagner
Gerhard Wagner
Recognition of the proper start codon on mRNAs is essential for protein synthesis, which requires scanning and involves eukaryotic initiation factors (eIFs) eIF1, eIF1A, eIF2, and eIF5. The carboxyl terminal domain (CTD) of eIF5 stimulates 43S preinitiation complex (PIC) assembly; however, its precise role in scanning and start codon selection has remained unknown. Using nuclear magnetic resonance (NMR) spectroscopy, we identified the binding sites of eIF1 and eIF2β on eIF5-CTD and found that they partially overlapped. Mutating select eIF5 residues in the common interface specifically disrupts interaction with both factors. Genetic and biochemical evidence indicates that these eIF5-CTD mutations impair start codon recognition and impede eIF1 release from the PIC by abrogating eIF5-CTD binding to eIF2β. This study provides mechanistic insight into the role of eIF5-CTD's dynamic interplay with eIF1 and eIF2β in switching PICs from an open to a closed state at start codons.